Li-Wei Tsai

Dr. Li-Wei Tsai

National Taiwan University College of Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
PLPo‐Han Lin
Po‐Han Lin
MCMing Chen
Ming Chen
LTLi-Wei Tsai
Li-Wei Tsai
CLChiao Lo
Chiao Lo
TYTzu‐Chun Yen
Tzu‐Chun Yen
CHChiun-Sheng Huang
Chiun-Sheng Huang
BRCAnessis considered a predictive biomarker to platinum and poly(ADP‐ribose) polymerase (PARP) inhibitors. However, recent trials showed that its predictive value was limited in triple‐negative breast cancer (TNBC) treated with platinum. Moreover, tumors with mutations of DNA damage response (DDR) genes, such as homologous recombination (HR) genes, could be sensitive to platinum and PARP inhibitors. Thus, we aim to explore the relationship between mutation status of DDR genes andBRCAnessin TNBC. We sequenced 56 DDR genes in 120 TNBC and identifiedBRCAnessby array comparative genomic hybridization. The sequencing results showed that 13, 14, and 14 patients hadBRCA, non‐BRCAHR, and non‐HR DDR gene mutations, respectively. Array comparative genomic hybridization revealed thatBRCA‐mutated and HR gene‐mutated TNBC shared similarBRCAnessfeatures, both having higher numbers and longer length of large‐scale structural aberration (LSA, >10 Mb) and similar altered chromosomal regions of LSA. These suggested non‐BRCAHR gene‐mutated TNBC shared similar characteristics withBRCA‐mutated TNBC, indicating non‐BRCAHR gene‐mutated TNBC sensitive to platinum and PARP inhibitors. Among tumors with mutation of non‐HR DDR genes, 3PTENand 1MSH6mutation also contained significant LSAs (BRCAness); however, they had different regions of genomic alteration toBRCAand HR gene‐mutated tumors, might explain prior findings thatPTEN‐andMSH6‐mutated cancer cells not sensitive to PARP inhibitors. Therefore, we hypothesize that the heterogeneous genomic background ofBRCAnessindicates different responsiveness to platinum and PARP inhibitors. Direct sequencing DDR genes in TNBC should be applied to predict their sensitivity toward platinum and PARP inhibitors.

Verified
Journal Article
Open access
PDF file
JLJie-Ning Li
Jie-Ning Li
PCPai-Sheng Chen
Pai-Sheng Chen
Ching-Feng ChiuChing-Feng Chiu
Ching-Feng Chiu
YLYu-Jhen Lyu
Yu-Jhen Lyu
CLChiao Lo
Chiao Lo
MWmingyang wang
mingyang wang
TAR (HIV-1) RNA binding protein 2 (TARBP2) is an RNA-binding protein participating in cytoplasmic microRNA processing. Emerging evidence has shown the oncogenic role of TARBP2 in promoting cancer progression, making it an unfavorable prognosis marker for breast cancer. Hypoxia is a hallmark of the tumor microenvironment which induces hypoxia-inducible factor-1α (HIF-1α) for transcriptional regulation. HIF-1α is prone to be rapidly destabilized by the ubiquitination–proteasomal degradation system. In this study, we found that TARBP2 expression is significantly correlated with induced hypoxia signatures in human breast cancer tissues. At a cellular level, HIF-1α protein level was maintained by TARBP2 under either normoxia or hypoxia. Mechanistically, TARBP2 enhanced HIF-1α protein stability through preventing its proteasomal degradation. In addition, downregulation of multiple E3 ligases targeting HIF-1α (VHL, FBXW7, TRAF6) and reduced ubiquitination of HIF-1α were also induced by TARBP2. In support of our clinical findings that TARBP2 is correlated with tumor hypoxia, our IHC staining showed the positive correlation between HIF-1α and TARBP2 in human breast cancer tissues. Taken together, this study indicates the regulatory role of TARBP2 in the ubiquitination–proteasomal degradation of HIF-1α protein in breast cancer.

9 July 2019 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
PYPo-Sheng Yang
Po-Sheng Yang
YLYi-Hsuan Lee
Yi-Hsuan Lee
CCChi-Feng Chung
Chi-Feng Chung
YCYuan-Ching Chang
Yuan-Ching Chang
MWMing-Yang Wang
Ming-Yang Wang
CHChiun-Sheng Huang
Chiun-Sheng Huang
Background: The information of Oncotype DX applied in Asian breast cancer patients is limited. A recurrence index for distant recurrence (RI-DR) has been developed for early-stage breast cancer (EBC) from tumor samples in Chinese patients. In this study, we compared the prognostic performance of the Oncotype DX (ODx) recurrence score (RS) with the RI-DR for any recurrence risk type.Materials and methods: One hundred thirty-eight (138) patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC who were previously tested with ODx were included for testing with the RI-DR. The cutoff score to partition the low- and high-risk patients was 26 for RS and 36 for RI-DR. The primary endpoint was recurrence-free survival (RFS).Results: The concordance between the RI-DR and RS was 83% in N0 patients and 81% in node-positive patients when the RS score cutoff was set at 26. With a median follow-up interval of 36.8 months, the 4-year RFS for the high- and low-risk groups categorized by the RS were 61.9% and 95.0%, respectively (hazard ratio: 10.6, 95.0% confidence interval [CI]: 1.8–62.9). The 4-year RFS in the high- and low-risk groups categorized by the RI-DR were 72.6% and 98.5%, respectively (hazard ratio: 18.9, 95% CI: 1.8–138.8).Conclusion: This paper illustrated the performance of RI-DR and ODx RS in breast cancer women in Taiwan. There was high concordance between the RI-DR and RS. The RI-DR is not inferior to the RS in predicting RFS in EBC patients. This study will fill the gap between the current and best practice in Chinese patients.

1 January 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PLPo-Han Lin
Po-Han Lin
LTLi-Wei Tsai
Li-Wei Tsai
CLChiao Lo
Chiao Lo
SKSung-Hsin Kuo
Sung-Hsin Kuo
CNChia-Chun Ni
Chia-Chun Ni
CHChiun-Sheng Huang
Chiun-Sheng Huang
CtDNA has been reported as a predictor of the progression of metastatic breast cancer and recurrence in early breast cancer (EBC). This study explored whether ctDNA persistence in patients with HER2-positive (HER2+) EBC who achieved pathologic complete response (pCR) after neoadjuvant therapy (NAT) indicates a poor prognosis and the need for adjuvant T-DM1. Of the 117 patients enrolled, 25 patients achieved pCR after NAT and 92 patients did not. Six of the 25 pCR patients showed positive ctDNA after NAT, whereas 26 of the 92 non-pCR patients were ctDNA-positive. Eighteen patients received adjuvant T-DM1, whereas 99 patients did not. Among the non–T-DM1 group, ctDNA positivity after NAT independently predicted recurrence (HR, 5.505; 95% confidence interval, 1.950–15.540; P = 0.001). pCR patients with ctDNA positivity experienced a shorter recurrence-free survival (RFS) compared with pCR and ctDNA-negative patients after NAT(P = 0.008), whereas non-pCR patients with ctDNA-negative tumors had a better RFS compared with non-pCR patients with ctDNA-positive status (P = 0.001). In the 79 patients who were ctDNA-positive before NAT, clearance of ctDNA by NAT was associated with significantly better RFS than nonclearance (P < 0.001). Adjuvant T-DM1 also significantly improved the ctDNA clearance rate (P = 0.035) compared with non–T-DM1 therapy in patients with ctDNA positivity after NAT during serial tests. We classified the 117 patients as T-DM1/non–T-DM1 and ctDNA-positive/negative, and a significantly shorter RFS was observed in patients with ctDNA-positive/non–T-DM1 (P = 0.029) than in the other three patient groups. In conclusion, the presence of ctDNA after NAT in patients with HER2+ EBC is associated with a poor prognosis and may indicate adjuvant T-DM1. Significance: Adjuvant T-DM1 can improve the survival of HER2+ EBC patients who don’t achieve pCR. Our study showed that ctDNA positivity after NAT was associated with decreased RFS. ctDNA-positive status after NAT can be switched to ctDNA-negative status in patients treated with T-DM1. Patients who were ctDNA-positive and treated with T-DM1 had a similar RFS to those who were ctDNA-negative, indicating that “ctDNA positivity” could be a marker determining adjuvant T-DM1 therapy.

16 September 2025 in European Journal of Radiology
Verified
Journal Article
Closed access
NCNing Chien
Ning Chien
YCYi-Hsuan Cho
Yi-Hsuan Cho
MWMing-Yang Wang
Ming-Yang Wang
LTLi-Wei Tsai
Li-Wei Tsai
CYCheng-Ya Yeh
Cheng-Ya Yeh
YCYeun-Chung Chang
Yeun-Chung Chang

7 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
HHuang Meng-Chuan
Huang Meng-Chuan
THTz-Ting Huang
Tz-Ting Huang
HFHsin-Chun Feng
Hsin-Chun Feng
ICI-Chun Chen
I-Chun Chen
CCChiao-I Chang
Chiao-I Chang
CLCHING-HUNG LIN
CHING-HUNG LIN
Although the incidence of invasive breast cancer (BC) among women in Asian is generally lower than that in Western countries, the incidence of BC has been on the rise in the past three decades in Asian countries. This hospital-based case-control study aimed to explore the relationship between dietary and metabolic factors and BC risk in pre- and post-menopausal women. We enrolled 285 patients with newly diagnosed BC at the National Taiwan University Hospital and 297 controls from the local community and hospital staff. Before receiving anticancer therapy, all patients with BC and control participants completed a 57-question semi-quantitative Food Frequency Questionnaire. For pre-menopausal women, plant-based factor scores rich in seeds and nuts, soy, fruits, and seaweeds correlated significantly with reduced BC risks, whereas menarche occurring at <12 years of age, reduced physical activity, and high-density lipoprotein <40 mg/dL were associated with increased BC risks. For post-menopausal women, plant-based dietary factor scores were also associated with reduced risks, whereas increased body mass index and energy intake levels correlated with increased BC risks. Diets rich in plant-based dietary patterns are protective against BC risk, regardless of menopausal status. Habitual physical activity is protective against BC risk among pre-menopausal Taiwanese women. Maintaining optimal weight and caloric intake is beneficial for reducing post-menopausal BC risk.